Lenvatinib Mesylate and Pepcid Oral Suspension
Determining the interaction of Lenvatinib Mesylate and Pepcid Oral Suspension and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using famotidine together with lenvatinib can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. According to the manufacturer, prolongation of the QT interval has been reported very rarely in patients with impaired renal function whose dose/dosing interval of famotidine may not have been adjusted appropriately. In general, the risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).
MANAGEMENT: Caution and clinical monitoring are recommended if famotidine is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.
- "Product Information. Pepcid (famotidine)." Merck & Co, Inc, West Point, PA.
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: lenvatinib
Brand name: Lenvima, Lenvima 8 mg daily-dose, Lenvima 20 mg daily-dose, Lenvima 12 mg daily-dose
Synonyms: Lenvatinib
Generic Name: famotidine
Brand name: Pepcid Oral Suspension, Pepcid, Heartburn Relief, Pepcid AC, Pepcid AC Maximum Strength, Pepcid AC Chewable Tablets
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Lenvatinib Mesylate-Peptic Relief
- Lenvatinib Mesylate-Pepto-Bismol
- Lenvatinib Mesylate-Pepto-Bismol (Bismuth Subsalicylate Chewable Tablets)
- Lenvatinib Mesylate-Pepto-Bismol (Bismuth Subsalicylate Suspension)
- Lenvatinib Mesylate-Pepto-Bismol (Bismuth Subsalicylate Tablets)
- Lenvatinib Mesylate-Peramivir
- Pepcid Oral Suspension-Lenvima
- Pepcid Oral Suspension-Lenvima (14 MG Daily Dose)
- Pepcid Oral Suspension-Lenvima (18 MG Daily Dose)
- Pepcid Oral Suspension-Lenvima (20 MG Daily Dose)
- Pepcid Oral Suspension-Lenvima (24 MG Daily Dose)
- Pepcid Oral Suspension-Lenvima (8 MG Daily Dose)